SWITCHING FROM INFLIXIMAB ORIGINATOR TO A BIOSIMILAR DOES NOT AFFECT PHARMACOKINETICS, IMMUNOGENICITY AND EFFICACY IN PEDIATRIC PATIENTS WITH INFLAMMATORY BOWEL DISEASE

被引：0
|
作者：
van Hoeve, Karen
Dreesen, Erwin
Hoffman, Ilse
Ferrante, Marc
Ann, Gils
Vermeire, Severine
机构：
来源：
GASTROENTEROLOGY | 2019年 / 156卷 / 06期
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
879
引用
收藏
页码：S199 / S199
页数：1
相关论文
共 50 条
  • [41] Switching patients with inflammatory bowel disease from originator to biosimilar SB2 infliximab: A single-center Australian longitudinal study
    Llewelyn, J.
    Radford-Smith, G.
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2021, 36 : 123 - 123
  • [42] SWITCHING FROM INFLIXIMAB ORIGINATOR TO THE BIOSIMILAR (CT-P13) IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE: A RETROSPECTIVE STUDY ABOUT EFFECTIVENESS AND SAFETY
    Annulli, G.
    Quatraccioni, C.
    Daretti, L. M.
    Antuono, S.
    Guardati, P.
    Calzolari, M.
    Benedetti, A.
    Di Sario, A.
    DIGESTIVE AND LIVER DISEASE, 2020, 52 : S134 - S135
  • [43] Mandatory non-medical switching policy from originator to biosimilar infliximab in patients with inflammatory bowel disease in British Columbia: A cohort study
    Fisher, Anat
    Kim, Jason D.
    Dormuth, Colin
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2022, 31 : 133 - 133
  • [44] Long-term effectiveness and pharmacokinetics of the infliximab biosimilar CT-P13 after switching from the originator during the treatment of inflammatory bowel disease
    Martin-Gutierrez, Nerea
    German Sanchez-Hernandez, Jose
    Rebollo, Noemi
    Pordomingo, Alejandra F.
    Munoz, Fernando
    Jose Otero, Maria
    EUROPEAN JOURNAL OF HOSPITAL PHARMACY, 2022, 29 (04) : 222 - 227
  • [45] Switching of Patients With Inflammatory Bowel Disease From Original Infliximab (Remicade®) to Biosimilar Infliximab (Remsima™) Is Effective and Safe
    Kolar, Martin
    Duricova, Dana
    Bortlik, Martin
    Hruba, Veronika
    Machkova, Nadezda
    Mitrova, Katarina
    Malickova, Karin
    Lukas, Martin
    Lukas, Milan
    GASTROENTEROLOGY, 2016, 150 (04) : S416 - S416
  • [46] Switching of patients with inflammatory bowel disease from original infliximab (Remicade®) to biosimilar infliximab (Remsima™) is effective and safe
    Kolar, M.
    Duricova, D.
    Brotlik, M.
    Hruba, V.
    Machkova, N.
    Mitrova, K.
    Malickova, K.
    Lukas, M.
    Lukas, M.
    JOURNAL OF CROHNS & COLITIS, 2016, 10 : S45 - S46
  • [47] PROSPECTIVE EVALUATION OF THE SAFETY AND EFFICACY OF SWITCHING STABLE PATIENTS WITH INFLAMMATORY BOWEL DISEASE FROM REMICADE™ TO BIOSIMILAR INFLIXIMAB (IFX)
    Bennett, K. J.
    Heap, G. A.
    Hawkins, S.
    Ahmad, T.
    GUT, 2016, 65 : A146 - A146
  • [48] Switching Patterns Among Patients with Chronic Inflammatory Diseases Switching to an Infliximab Biosimilar or Remaining on Originator Infliximab (REMICADE)
    Emond, Bruno
    Sadik, Kay
    Lafeuille, Marie-Helene
    Wynant, Willy
    Cote-Sergent, Aurelie
    Lefebvre, Patrick
    Woodruff, Kimberly
    Fitzgerald, Timothy
    ARTHRITIS & RHEUMATOLOGY, 2019, 71
  • [49] Switching from infliximab to biosimilar in inflammatory bowel disease: overview of the literature and perspective
    Milassin, Agnes
    Fabian, Anna
    Molnar, Tames
    THERAPEUTIC ADVANCES IN GASTROENTEROLOGY, 2019, 12
  • [50] Similar Growth Outcomes in Children with Inflammatory Bowel Disease Initiated on Infliximab Originator or Biosimilar
    Mcclinchie, Madeline G.
    Lakhani, Alyshah
    Abdel-Rasoul, Mahmoud
    Mcnicol, Megan
    Shkhkhalil, Ala K.
    Boyle, Brendan B.
    Maltz, Ross M.
    JOURNAL OF PEDIATRIC GASTROENTEROLOGY AND NUTRITION, 2023, 77 (04): : 499 - 504
12345